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Letters to the Editor
Activity of Temocillin against KPC-Producing Klebsiella pneumoniae and
Escherichia coli
Temocillin, a 6--methoxy derivative of ticarcillin, is cur-
rently approved for treatment of infections due to members
of the Enterobacteriaceae in Belgium and the United King-
dom. It is stable against hydrolysis by most -lactamases,
including extended-spectrum -lactamases (ESBLs) and
AmpC-type -lactamases, with studies reporting MICs at
which 90% of bacteria are inhibited (MIC90s) between 16
and 32 g/ml (3, 4, 8). Temocillin is thus drawing attention
as a potential alternative to carbapenems in treatment of
infections caused by the Enterobactericeae producing these
broad-spectrum -lactamases.
Carbapenem-resistant Klebsiella pneumoniae producing
KPC-type -lactamase has emerged in recent years and
caused hospital outbreaks of serious infections in the United
States and other parts of the world (7). Furthermore, KPC-
type -lactamase is increasingly identified in other species of
the Enterobacteriaceae as well, including Escherichia coli.
One concerning recent phenomenon is the occurrence of
urinary tract infections due to KPC-producing organisms at
nursing homes (10). Currently, the limited treatment op-
tions for infections due to KPC-producing organisms in-
clude colistin and tigecycline. Concern over nephrotoxicity
due to colistin limits its use outside closely monitored set-
tings, whereas tigecycline does not achieve a therapeutic
concentration in urine (2). Furthermore, emergence of re-
sistance to these agents has recently been recorded for the
Enterobacteriaceae (5, 6).
The present study was conducted to evaluate the in vitro
activities of temocillin against clinical isolates of K. pneu-
moniae and E. coli producing KPC-type -lactamase. A total of
33 KPC-producing clinical isolates (30 K. pneumoniae isolates
and 3 E. coli isolates) were used. KPC production was con-
firmed by an ertapenem resistance phenotype, a positive mod-
ified Hodge test, and positive PCR for the KPC structural
gene. The isolates were collected from hospitals in three states
in the United States. The MIC of temocillin was determined by
the standard agar dilution method (1). Temocillin was pro-
vided by Eumedica (Brussels, Belgium). In addition, MICs of
temocillin against an E. coli isogenic clone producing KPC-3
were tested to determine the direct effect of KPC production
on the temocillin MIC. E. coli ATCC 25922 was used as the
control strain.
Table 1 summarizes the results. For K. pneumoniae, the
MICs ranged between 16 g/ml and 64 g/ml (MIC at which
50% of bacteria were inhibited  32 g/ml; MIC90  32
g/ml). The E. coli clinical isolates had MICs between 8 and
16 g/ml. E. coli DH10B both with and without the cloning
vector pBCSK (Stratagene, La Jolla, CA) encoding
blaKPC-3 had an MIC of 8 g/ml. An inoculum effect was not
observed at 105 CFU, whereas a mild inoculum effect aver-
aging within a twofold MIC difference was seen with K.
pneumoniae when 106 CFU was inoculated (Table 1). This
result was in line with those of a previous study documenting
a modest inoculum effect of temocillin for non-KPC-pro-
ducing isolates (9). The frequencies of mutants of represen-
tative clinical isolates that grew at their MICs and at 2
MICs were calculated to be approximately 1  1010 and 0
for K. pneumoniae and 3  1010 and 1  1010 for E. coli,
respectively.
Currently, the British Society for Antimicrobial Chemother-
apy (BSAC) is the only organization that defines temocillin
MIC breakpoints for the Enterobacteriaceae. The BSAC de-
fines temocillin susceptibilities at 8 and 32 g/ml in sys-
temic and urinary tract infections, respectively (http://www
.bsac.org.uk/). One gram of temocillin is known to achieve a
peak serum concentration of approximately 160 g/ml, with
serum binding of 85% and a half-life of 4 to 5 h (9). The
urinary concentration after a 500-mg dose is approximately 500
g/ml (9). These pharmacokinetic properties of temocillin
make it a potential alternative treatment option for mild to
moderate urinary tract infections caused by KPC-producing
members of the Enterobacteriaceae.
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E. coli (3) 1 1 1
a n, no. of isolates.
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c BSAC breakpoint for urinary tract infections.
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